Fig. 1: Asb10 is downregulated in pathological cardiac hypertrophy in vitro and in vivo.

A Principal component analysis (PCA) of merged GEO datasets. N = 11. B Volcano plot of the merged GEO datasets. N = 11. C Heat map showing the relative expression of Asb10 and hypertrophic markers in merged GEO datasets. N = 11. D Validation of the relative Asb10 expression in cardiac tissue of sham and TAC mice from three GEO datasets, GSE79536, GSE136308 and GSE180720. N = 3 for GSE79536 and GSE180720, N = 5 (sham) and 4 (TAC) in GSE136308. E Validation of the relative Asb10 expression in cardiac tissue of donors, hypertrophic cardiomyopathy and heart failure patients from three GEO datasets, GES180313, GSE135055, GSE161472. N = 7 (Donor) and 13 (HCM) in GSE180313, N = 9 (Donor) and 13 (HF) in GSE135055, N = 4 (NF) and 5 (HF) in GSE161472. F In vitro validation of the protein expression of ASB10 in NRVMs treated with 50 μM PE for 24 h as determined by western blot. The right panel showed the densitometric quantification. N = 9. G In vitro validation of the mRNA expression of Asb10 in NRVMs treated with 50 μM PE for 24 h as determined by qPCR. N = 6. H Representative images of anti-ASB10 immunofluorescence staining in NRVMs treated with 50 μM PE for 24 h. Scale bar = 10 μm. The right panel showed the quantification. N = 6. I In vivo validation of the protein expression of ASB10 in heart tissue from mice treated with TAC surgery as determined by western blot. The right panel showed the densitometric quantification. N = 5. J In vivo validation of the mRNA expression of Asb10 in heart tissues from mice treated with TAC surgery as determined by qPCR. N = 5. Limma power differential expression analysis (B–E) was conducted. Unpaired Student’s t-test (F, G) was conducted. One-way ANOVA followed by Turkey’s multiple comparisons test was conducted (I, J). Data were represented as Mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ^nsP > 0.05.